Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 9/20 | 0.70 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.70 |
| ▸ | CDK2 | P24941 | 11/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.55 |
| ▸ | CDK1 | P06493 | 4/20 | 0.51 |
| ▸ | CDK4 | P11802 | 4/20 | 0.51 |
| ▸ | CCND1 | P24385 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388436 | 0.95 | CDK5 (0.80) | CDK5CDK5R1CDK2CCNA2CDK1 | |
| SCHEMBL14073856 | 0.88 | CDK5 (0.67) | CDK5CDK5R1CDK2CCNA2 | |
| SCHEMBL3384264 | 0.88 | CDK2 (0.64) | CDK5CDK5R1CDK2CCNA2CDK1 | |
| SCHEMBL3386774 | 0.87 | CDK5 (0.72) | CDK5CDK5R1CDK2CCNA2 | |
| SCHEMBL14073883 | 0.86 | CDK5 (0.64) | CDK5CDK5R1CDK2CCNA2CDK4 | |
| SCHEMBL14073863 | 0.86 | CDK5 (0.64) | CDK5CDK5R1CDK2CCNA2 | |
| SCHEMBL3386683 | 0.86 | CDK5 (0.74) | CDK5CDK5R1CDK2CCNA2 | |
| SCHEMBL14073872 | 0.85 | CDK5 (0.63) | CDK5CDK5R1CDK2CCNA2 | |
| SCHEMBL14073889 | 0.85 | CDK2 (0.53) | CDK5CDK5R1CDK2CCNA2CDK1 | |
| SCHEMBL28765718 | 0.84 | CDK5 (0.69) | CDK5CDK5R1CDK2CCNA2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771424-B1 | NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-15 | — | — | EP | claimed |
| US-7423053-B2 | 4-Aminothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | claimed |
| EP-1771424-A1 | NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-11 | — | — | EP | claimed |
| WO-2006005508-A1 | NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | claimed |
| EP-1771424-B1 | NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-15 | — | — | EP | disclosed |
| CN-1976910-B | 2, 4-diaminothiazol-5-one derivatives | HOFFMANN LA ROCHE | 2010-07-21 | — | — | CN | disclosed |
| US-7423053-B2 | 4-Aminothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423053-B2 | 4-Aminothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423053-B2 | 4-Aminothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| CN-1976910-A | Novel 2, 4-diaminothiazol-5-one derivatives | HOFFMANN LA ROCHE (CH) | 2007-06-06 | — | — | CN | disclosed |
| EP-1771424-A1 | NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006005508-A1 | NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
| US-20060014958-A1 | 4-Aminothiazole derivatives | CHEN LI | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014958-A1 | 4-Aminothiazole derivatives | CDK4, CDK2, CCNI | CDK5 19/4885CDK5R1 49/4885CDK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.